Association of Sodium-Glucose Cotransporter 2 Inhibitor Use With Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation: A Systematic Review and GRADE-Assessed Meta-Analysis

Cardiovasc Ther. 2026;2026(1):e8933859. doi: 10.1155/cdr/8933859.ABSTRACTBACKGROUND: Patients undergoing transcatheter aortic valve implantation (TAVI) remain at risk of adverse cardiovascular and renal outcomes despite procedural advancements. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have

A Ahmed Adel Mohamed

Cardiometabolic diseases in transgender populations

Cardiovasc Diabetol Endocrinol Rep. 2026 Oct 6;12(1):64. doi: 10.1186/s40842-026-00336-x.ABSTRACTThe number of people seeking gender-affirming medical care and gender-affirming hormone therapy (GAHT) is increasing. As sex steroids shape cardiometabolic physiology, GAHT is expected to meaningfully al

M Mattia Fienga

Feasibility, acceptability, and preliminary estimates of a multimodal AKTIVER Heart Delirium Prevention Program in patients indicated for cardiac surgery: study protocol of a randomized controlled PREVENT POstoperative Delirium (PREVENT-POD) Pilot Study

Pilot Feasibility Stud. 2026 Oct 5;12(1):142. doi: 10.1186/s40814-026-01923-6.ABSTRACTBACKGROUND: Postoperative delirium (POD) is a common complication in geriatric patients undergoing cardiac surgery. POD is associated with prolonged length of stay in the intensive care unit and hospital, increased

J Julia Kühnle